In patients with multiple scle

In the recently held United States Academy of Neurology (ANN) 2010 meeting, pointed out that, if multiple sclerosis (MS) terminates his nimotuzumab in patients with treatment, physicians should prepare candidates for treatment programmes to prevent disease recurrence and other complications.　　　Commentators said the United States that his beads monoclonal antibody drug users have three, in Europe, drug users have 58% of progressive multifocal leukoencephalopathy (PML). A recent small study shows that MS deactivated after he nimotuzumab in patients with no apparent adverse events, but it uses interferon or other drugs. Another study shows that take drugs without interferon, is quite a lot of MS patients with magnetic resonance imaging (MRI) detected during an inspection-related damage and disease may relapse after 60-90 days. www.cmt.com.cn